Advances in non-factor therapy: Towards individualised care for haemophilia
Sonata Šaulytė Trakymienė (Lithuania); Johnny Mahlangu (South Africa); Pratima Chowdary (UK)
MATERIALS AVAILABLE
Coming soon
18:30 - 19:30
CET
PO016
Publication
High-quality standardised ELISA to manage dose adjustments during concizumab prophylaxis in patients with haemophilia A/B with and without inhibitors in the routine clinical setting: Test access model description
Efficacy and safety of concizumab prophylaxis in patients with haemophilia and inhibitors: Results from the Early Access Program in France
Alexandre Butelet1; Nicolas Béranger2; Vincent Cussac2; Roseline d’Oiron3-6; Yesim Dargaud4-5; Victoria Delerue2; Stéphanie Desage5; Caroline Galeotti3; Sophie Susen7; Valérie Chamouard4-5
MATERIALS AVAILABLE
Poster
18:30 - 19:30
CET
PO049
Publication
Safety and efficacy of Mim8 prophylaxis once every two weeks in haemophilia A: A FRONTIER4 interim analysis
Tadashi Matsushita1; Pratima Chowdary2; Atanas Banchev3; Kaan Kavakli4; Johanna A. Kremer Hovinga5; Jerzy Windyga6; Victor Jiménez-Yuste7; Julien Bovet8; Llenalia María García Fernández9; Guy Young10
MATERIALS AVAILABLE
Poster
18:30 - 19:30
CET
PO057
Publication
Mim8 prophylaxis beyond bleeding: Multifaceted, patient-reported outcomes for haemophilia A in FRONTIER2
Carmen Escuriola-Ettinghausen1; Cihan Ay2; Cedric Hermans3; Peter Kampmann4; Rikke Medom Meldgaard5; Ilgiz Rakhmatullin5; Ciprian Tomuleasa6; Lize Fie Ditteke van Vulpen7; Michael Wang8; Irena Woznica Karczmarz9; Sophie Susen10
MATERIALS AVAILABLE
Poster
18:30 - 19:30
CET
PO070
Publication
Patient- and caregiver-reported outcomes with subcutaneous Mim8 prophylaxis in paediatric patients with haemophilia A with or without factor VIII inhibitors: Phase 3 FRONTIER3 study
Gili Kenet1; Matteo Luciani2; Paula Kjöllerström3; Rubén Berrueco4; Amalie Rhode Høgh Nielsen5; Jay Jay Thaung Zaw5; Karin FijnvanDraat6
MATERIALS AVAILABLE
Poster
18:30 - 19:30
CET
PO108
Publication
Expedited learning and enhanced usability of a pre-filled Mim8 pen injector for the management of haemophilia A
Lisha Shastri1; Greta Mulders2; Thomas Sparre1; Kelly C Bellm3; Gitte Ter-Borch4; Robert Sidonio Jr5
MATERIALS AVAILABLE
Poster
18:30 - 19:30
CET
PO041
Publication
Growing up with N9-GP: Safety and efficacy of prophylaxis for up to eleven years in children with haemophilia B
Manuel Carcao1; Karin Walsh2; Christine Mrakotsky3; Andrea Landorph4;Anthony KC Chan5
MATERIALS AVAILABLE
Poster
18:30 - 19:30
CET
PO067
Publication
Unmet needs of patients with haemophilia A/B with or without inhibitors: Real-world end-of-study results from the explorer6 non-interventional study
Annualised bleeding rates in patients with haemophilia A or B and inhibitors with and without target joints at baseline: Results from the concizumab phase 3 explorer7 study
Mim8 ex vivo Thrombin Generation Response Using Activated Factor XI Versus Tissue Factor as Trigger
Wan Hui Ong Clausen1; Ties Latendorf2; Rielana Stehr2; Damaris Bausch-Fluck3; and Jacob Lund4
MATERIALS AVAILABLE
Poster
18:30 - 19:30
CET
PO370
Publication
Exploring unmet patient needs in haemophilia: A qualitative study on joint bleed treatment in the US
Enrico Mastroianni1; Christian Brink Scholz2
MATERIALS AVAILABLE
Poster
Friday, 07 February 2025
08:30 - 10:00
CET
OR01
Publication
FRONTIER3: Safety and efficacy of Mim8 prophylaxis in paediatric patients with haemophilia A
Johnny Mahlangu1; M. Elaine Eyster2; Karin Fijnvandraat3; Gili Kenet4; Nita Radhakrishnan5; Irena Woznica-Karczmarz6; Runhui Wu7; Chur Woo You8; Andrea Paramo Florencio9; Jay Jay Thaung Zaw9; Manuel Carcao10